CTLA4 and melanoma: Three monoclonal antibodies directed to two different immune checkpoint molecules - CTLA-4 (cytotoxic T-lymphocyte antigen 4) and PD-1 (programmed death receptor 1) − have now been approved by the U.S. Food and Drug Administration for treatment of melanoma and NSCLC patients [1,2].